BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26070608)

  • 1. Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy.
    Desmeules P; Hovington H; Nguilé-Makao M; Léger C; Caron A; Lacombe L; Fradet Y; Têtu B; Fradet V
    Diagn Pathol; 2015 Jun; 10():67. PubMed ID: 26070608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
    Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
    Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
    Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
    Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer.
    Ritch CR; You C; May AT; Herrell SD; Clark PE; Penson DF; Chang SS; Cookson MS; Smith JA; Barocas DA
    Urology; 2014 Jun; 83(6):1309-15. PubMed ID: 24746665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional assessment of needle biopsy specimens is more useful than digital image analysis of proliferation and DNA ploidy in prediction of positive surgical margins at radical prostatectomy.
    Sengupta S; Cheville JC; Lohse CM; Zincke H; Myers RP; Riehle DL; Pankratz VS; Blute ML; Sebo TJ
    Urology; 2006 Jul; 68(1):94-8. PubMed ID: 16844452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study.
    Kim SH; Park WS; Park BR; Joo J; Joung JY; Seo HK; Chung J; Lee KH
    Asian J Androl; 2017; 19(4):458-462. PubMed ID: 27232854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
    Bettencourt MC; Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Moul JW
    J Urol; 1996 Sep; 156(3):1064-8. PubMed ID: 8709308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy.
    Léon P; Cancel-Tassin G; Drouin S; Audouin M; Varinot J; Comperat E; Cathelineau X; Rozet F; Vaessens C; Stone S; Reid J; Sangale Z; Korman P; Rouprêt M; Fromond-Hankard G; Cussenot O
    World J Urol; 2018 Sep; 36(9):1495-1500. PubMed ID: 29679140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.
    Briganti A; Wiegel T; Joniau S; Cozzarini C; Bianchi M; Sun M; Tombal B; Haustermans K; Budiharto T; Hinkelbein W; Di Muzio N; Karakiewicz PI; Montorsi F; Van Poppel H
    Eur Urol; 2012 Sep; 62(3):472-87. PubMed ID: 22633803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort.
    Richardsen E; Andersen S; Al-Saad S; Rakaee M; Nordby Y; Pedersen MI; Ness N; Grindstad T; Movik I; Dønnem T; Bremnes R; Busund LT
    PLoS One; 2017; 12(11):e0186852. PubMed ID: 29141018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of biochemical recurrence after radical prostatectomy using peritumoral lymphatic vessel density in biopsy specimens in patients with localized prostate cancer.
    Kuroda K; Horiguchi A; Asano T; Tasaki S; Yoshii H; Sato A; Asakuma J; Ito K; Seguchi K; Sumitomo M; Asano T
    Urol Int; 2012; 88(1):18-24. PubMed ID: 22222198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated Ki-67 (MIB-1) expression as an independent predictor for unfavorable pathologic outcomes and biochemical recurrence after radical prostatectomy in patients with localized prostate cancer: A propensity score matched study.
    Byun SS; Lee M; Hong SK; Lee H
    PLoS One; 2019; 14(11):e0224671. PubMed ID: 31697718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.
    Tollefson MK; Karnes RJ; Kwon ED; Lohse CM; Rangel LJ; Mynderse LA; Cheville JC; Sebo TJ
    Mayo Clin Proc; 2014 Mar; 89(3):308-18. PubMed ID: 24486077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of Akt-1 in human prostate cancer: a computerized quantitative assessment with quantum dot technology.
    Li R; Dai H; Wheeler TM; Sayeeduddin M; Scardino PT; Frolov A; Ayala GE
    Clin Cancer Res; 2009 May; 15(10):3568-73. PubMed ID: 19417030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
    Malik RD; Goldberg JD; Hochman T; Lepor H
    Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short (≤ 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy.
    Shikanov S; Marchetti P; Desai V; Razmaria A; Antic T; Al-Ahmadie H; Zagaja G; Eggener S; Brendler C; Shalhav A
    BJU Int; 2013 Apr; 111(4):559-63. PubMed ID: 22759270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue microarray sampling strategy for prostate cancer biomarker analysis.
    Rubin MA; Dunn R; Strawderman M; Pienta KJ
    Am J Surg Pathol; 2002 Mar; 26(3):312-9. PubMed ID: 11859202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
    Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
    Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
    May M; Siegsmund M; Hammermann F; Loy V; Gunia S
    Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.